HSBC assumed coverage on shares of Moderna (NASDAQ:MRNA – Get Free Report) in a report released on Friday, MarketBeat.com reports. The brokerage set a “reduce” rating and a $97.00 price target on the stock. HSBC’s target price would suggest a potential downside of 20.07% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the company. 51job restated an “upgrade” rating on shares of Moderna in a research note on Monday, June 26th. Morgan Stanley lowered their price objective on Moderna from $185.00 to $153.00 in a research note on Friday, May 5th. UBS Group upgraded Moderna from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $221.00 to $191.00 in a research note on Monday, June 26th. JPMorgan Chase & Co. boosted their price objective on Moderna from $127.00 to $145.00 and gave the company a “neutral” rating in a research note on Monday, April 10th. Finally, Guggenheim assumed coverage on Moderna in a research note on Tuesday, April 25th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $175.00.
Moderna Trading Down 4.2 %
NASDAQ MRNA opened at $121.35 on Friday. The stock has a market capitalization of $46.26 billion, a price-to-earnings ratio of 10.49 and a beta of 1.63. Moderna has a one year low of $115.03 and a one year high of $217.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.46 and a quick ratio of 3.26. The business’s fifty day moving average is $125.74 and its 200-day moving average is $148.31.
Insider Transactions at Moderna
In other news, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $130.61, for a total transaction of $5,224,400.00. Following the completion of the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $706,854,267.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $130.61, for a total value of $5,224,400.00. Following the completion of the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $706,854,267.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 250 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $133.37, for a total value of $33,342.50. Following the completion of the sale, the president now directly owns 1,630,732 shares of the company’s stock, valued at approximately $217,490,726.84. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 414,005 shares of company stock valued at $53,103,075. 15.70% of the stock is owned by corporate insiders.
Institutional Trading of Moderna
A number of institutional investors have recently made changes to their positions in MRNA. Ronald Blue Trust Inc. boosted its stake in shares of Moderna by 307.4% during the fourth quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock valued at $26,000 after purchasing an additional 166 shares during the period. Roble Belko & Company Inc bought a new position in shares of Moderna during the fourth quarter valued at approximately $27,000. ICA Group Wealth Management LLC bought a new position in shares of Moderna during the fourth quarter valued at approximately $27,000. GHP Investment Advisors Inc. raised its holdings in shares of Moderna by 208.3% during the first quarter. GHP Investment Advisors Inc. now owns 185 shares of the company’s stock valued at $28,000 after acquiring an additional 125 shares in the last quarter. Finally, Stone House Investment Management LLC bought a new position in shares of Moderna during the first quarter valued at approximately $36,000. Hedge funds and other institutional investors own 70.44% of the company’s stock.
About Moderna
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.
Featured Articles
- Five stocks we like better than Moderna
- MarketBeat Week in Review – 7/10 – 7/14
- Wells Fargo’s Earnings, Why Markets Are Loving The Stock
- Citigroup Leads Banking Earnings, What’s Next?
- BlackRock Kicks Off Financials Earnings Season, Gauge To Markets
- JPMorgan Chase Is In Reversal But Don’t Chase It Higher
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
-logo.jpg?v=20230511062707&h=45&w=95&zc=2){kind=logo}
